Portugal-headquartered digital health company Hope Care has raised €6 million in new capital to expand its regulated remote patient monitoring technology across Europe.
The Series A round was led by Iberis Capital, with participation from Vieira de Matos – Vdm Capital, S.A. and existing shareholder Buenavista Equity Partners, according to a press statement from the company.
Hope Care said the funding will support its continued European expansion, strengthen its commercial and operational capabilities, and accelerate the deployment of remote patient monitoring programs in key healthcare markets.
Expansion across European markets
The company currently delivers remote patient monitoring programs in Portugal and France, including within GHT Saône-et-Loire Bresse Morvan, and has a project underway in Switzerland.
In Germany, Hope Care has recently established Hope Care GmbH, headquartered at Medical Valley in Erlangen. Its first German deployment is scheduled to launch in October 2026.
The company is also advancing a project in Romania and establishing a local presence, with setup activities scheduled to begin by the end of September 2026.
In Portugal, Hope Care said its technology is used by 15 Local Health Units covering approximately 45% of all registered SNS users, as well as the Regional Health Services of Madeira and the Azores. Its platform is also used by private healthcare providers, social care organizations, and municipalities.
How Hope Care’s remote monitoring platform works
Hope Care develops OpMA®, a regulated platform used to operate centralized remote care and telehealth centers.
The platform brings together medical-device data, patient-reported outcomes, and clinical workflows, allowing healthcare organizations to design and operate digital care programs across multiple chronic conditions.
OpMA® is the commercial name of HCAlert V1.3, which is certified as a Class IIb Software as a Medical Device under Regulation (EU) 2017/745.
Sales growth and clinical results
Hope Care reported that sales in the first half of 2026 reached 2.5 times the level recorded during the same period in 2025.
The company also cited a 12-month analysis of 43 people living with chronic obstructive pulmonary disease. According to Hope Care, the program was associated with a 76% reduction in hospital days and a 74% reduction in emergency department visits, resulting in estimated annual savings of €4,811 per patient.
“This Series A marks a new stage for Hope Care,” said José Paulo Carvalho, founder and CEO of Hope Care. “After more than a decade working with healthcare institutions, we have built a regulated platform that delivers measurable outcomes for patients, healthcare professionals, and healthcare systems.”
João Henriques, partner at Iberis Capital, said European health systems are facing growing pressure from chronic disease and pointed to Hope Care’s clinical evidence and regulatory maturity.
“Hope Care is one of the few companies that pairs proven clinical evidence with the regulatory maturity to operate inside public health systems at scale,” Henriques said, adding that the model can help improve patient outcomes and support the sustainability of care.
Featured image: Featured image: (From left) José Paulo Carvalho (founder and CEO), Célia Carmo (chief financial officer), and Manuel Bragança Pereira (chief medical officer) – Photo courtesy of Hope Care
Portugal Startup News 